Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

AIM ImmunoTech Inc.

CIK 946644 AIM·Biological Products · All EDGAR filings ↗

Accounting standard newly cited Filing comparison

AIM ImmunoTech Inc. cited accounting standards ASU 2023-09, ASU 2025-05, ASU 2025-11 for the first time in this filing series

The adoption of ASU 2023-09 did not result in any material changes to the consolidated financial statements or income tax disclosures.
Evidence
Adopted
2023-09, 2025-05, 2025-11
Contexts
The adoption of ASU 2023-09 did not result in any material changes to the consolidated financial statements or income tax disclosures., During the fiscal year ended December 31, 2025, the Company adopted the following ASUs: ASU 2025-05, Financial Instruments- Credit Losses (Topic 326): Measurements of Credit Losses of Accounts Receivable and Contract Asset; ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, and ASU 2025-12, Codification Improvements., During the fiscal year ended December 31, 2025, the Company adopted the following ASUs: ASU 2025-05, Financial Instruments- Credit Losses (Topic 326): Measurements of Credit Losses of Accounts Receivable and Contract Asset; ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, and ASU 2025-12, Codification Improvements.
New standards
2023-09, 2025-05, 2025-11, 2025-12
Prior filed
2025-03-27
Prior form
10-K
Restates existing policy
No
Source
accounting standards update (ASU) reference comparison
Why
An accounting standard (ASU) appears in this filing that did not appear in the previous comparable one, in a sentence describing it as adopted. That is a change in what the company discloses, which is not always a change of policy in the current period: the filing may state an adoption date years earlier.